Late clinical development (PHASE III) & Post-Approval

TempO-Seq features render it particularly suitable for profiling and stratifying large cohorts of patients from commonly used clinical sample types, such as biopsies, FFPE tissue, whole blood, or plasma. TempO-Seq allows for efficient analysis of large sample numbers with fully customisable biomarker panels of tens to thousands of genes (up to the whole transcriptome).

Unlike many other technologies, TempO-Seq offers unlimited gene multiplexing. Therefore, biomarker panels for patient stratification can include as many genes and variants as are necessary. Extra genes can be added on at virtually no extra cost. Importantly, the TempO-Seq assay does not require any proprietary instrumentation, runs in a simple 96- or 384-well plate format in < 6 h (with less than an hour hands-on time), and can therefore be easily implemented in a real-world clinical setting.

Therefore, TempO-Seq is ideally suited for development of Companion Diagnostics (CDx).

Regardless of whether you would like to implement known signatures with a TempO-Seq assay or develop a new signature based on TempO-Seq data, please feel free to contact us. Our team is happy to support CDx development activities.